Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Talazoparib/Enzalutamide Combo Meets rPFS End Point in Untreated Metastatic CRPC

October 4th 2022

The addition of talazoparib to enzalutamide produced a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs enzalutamide plus placebo in previously untreated patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.

Rucaparib Meets rPFS End Point in BRCA/ATM-Mutated mCRPC

October 3rd 2022

Single-agent rucaparib significantly improved radiographic progression-free survival vs chemotherapy or second-line androgen deprivation therapy in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer harboring BRCA or ATM mutations.

FDA Accepts NDA for 18F-rhPSMA-7.3 as Diagnostic Imaging Tool in Prostate Cancer

September 29th 2022

The FDA has accepted for review a new drug application for 18F-rhPSMA-7.3, an investigational radiohybrid PSMA-targeted PET imaging agent for diagnostic imaging of prostate cancer, according to an announcement from Blue Earth Diagnostics.

AZD4635 Plus Durvalumab or Oleclumab Has Minimal Clinical Activity in mCRPC

September 26th 2022

The addition of AZD4635 to durvalumab or oleclumab did not elicit significant responses in heavily pretreated patients with metastatic castration-resistant prostate cancer.

Dr. Moon on the Future of Care in Prostate Cancer

September 21st 2022

Helen Heng-Shan Moon, MD, discusses the future of care in prostate cancer.

Exploring High-Intensity Focused Ultrasound as an Organ-Sparing Option for Prostate Cancer

September 21st 2022

The definitive treatment of prostate cancer has historically relied on whole-gland treatment.

Enzalutamide Plus ADT Improves rPFS, OS in Metastatic HSPC With Prior ADT

September 20th 2022

Enzalutamide plus androgen deprivation therapy elicited significant improvements in radiographic progression-free survival and overall survival vs placebo in patients with metastatic hormone-sensitive prostate cancer.

PSA Decline After Lutetium Lu 177 Vipivotide Tetraxetan Treatment Prolongs Survival in PSMA-Positive mCRPC

September 13th 2022

The decline of prostate-specific antigen following treatment with lutetium Lu 177 vipivotide tetraxetan plus standard of care was linked with prolonged radiographic progression-free survival and overall survival in patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Pembrolizumab/Olaparib Combo Fails to Improve rPFS, OS Vs Novel Hormonal Agents in mCRPC

September 12th 2022

The combination of pembrolizumab and olaparib did not significantly improve radiographic progression-free survival and overall survival compared with novel hormonal agents in patients with molecularly unselected, previously treated metastatic castration-resistant prostate cancer.

Two Years Post-operative ADT Plus Radiotherapy Improves MFS, Time to Salvage Therapy in Prostate Cancer

September 12th 2022

The addition of 24 months of androgen deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved time to salvage therapy in patients with prostate cancer.

Apalutamide Plus ADT Elicits PSA PFS Benefit in High-Risk, Biochemically Relapsed Prostate Cancer

September 11th 2022

Intensification of androgen-deprivation therapy plus apalutamide displayed promising efficacy in patients with high-risk, biochemically relapsed prostate cancer.

Olaparib/Abiraterone Continues to Provide Superior Clinical Benefit Over Abiraterone Alone in Frontline mCRPC

September 11th 2022

The combination of olaparib plus abiraterone acetate and prednisone or prednisolone demonstrated a continuing trend toward an overall survival benefit when used in the first-line treatment of patients with metastatic castration-resistant prostate cancer.

Addition of Enzalutamide to Abiraterone/Prednisolone Deemed Unnecessary in Metastatic HSPC

September 11th 2022

Although the combination of androgen deprivation therapy, abiraterone acetate, and prednisolone showed a clinically meaningful 7-year improvement in overall survival, AAP plus enzalutamide is not recommended in patients with metastatic hormone-sensitive prostate cancer.

Pembrolizumab Plus Abiraterone/Prednisone Shows Sustained Efficacy in Chemotherapy-Naïve mCRPC

September 10th 2022

Pembrolizumab plus abiraterone acetate and prednisone demonstrated continued efficacy and tolerability in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.

AI-Powered Focal Therapy Maps Future Treatment Paradigm in Prostate Cancer

September 8th 2022

For clinicians tasked with treating patients with prostate cancer, disease visualization has traditionally consisted of imprecise techniques such as MRI. However, a new artificial intelligence-based approach by Avenda Health is poised to potentially revolutionize the treatment landscape in the field.

Investigative Approaches Seek to Enhance Outcomes for Patients With CDK12-Mutant mCRPC

September 3rd 2022

DNA damage homologous recombination repair genotypic variants are not created equal.

Practical Considerations in Selecting Therapy for Metastatic CRPC

August 23rd 2022

Closing out their discussion on prostate cancer, expert panelists highlight which factors best inform selection of therapy for patients with mCRPC.

What is the Role of 177Lu-PSMA-617 in Metastatic CRPC?

August 23rd 2022

Panelists share insight on 177Lu-PSMA-617 and consider where it might fit into the treatment paradigm for metastatic castration-resistant prostate cancer.

Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer

August 22nd 2022

Dr Petrylak discusses current issues with genetic testing and disease management in prostate and bladder cancer, some of the reasons for poor testing rates, and the importance of proper multidisciplinary management during testing and when seeking to mitigate adverse effects.

FDA Grants Priority Review to Olaparib/Abiraterone Regimen in Metastatic Castration-Resistant Prostate Cancer

August 16th 2022

The FDA has granted priority review to a supplemental new drug application seeking the approval of olaparib in combination with abiraterone acetate and prednisone or prednisolone in adult patients with metastatic castration-resistant prostate cancer.